More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5575602
EPS
--
P/E ratio
--
Price to sales
9.35
Dividend yield
--
Beta
1.62801
Previous close
$1.15
Today's open
$1.19
Day's range
$1.11 - $1.29
52 week range
$1.11 - $3.95
show more
CEO
Philip A. Serlin
Employees
24
Headquarters
Modiin,
Exchange
NASDAQ Capital Market
Shares outstanding
4978216
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd.
PRNewsWire • 10 hours ago

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties - - Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts - - BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid - TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P.
PRNewsWire • 12 hours ago

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting - - GLIX1 demonstrated robust, dose-dependent antitumor activity in multiple GBM models, including confirmed evidence of brain penetration and dose-dependent increases in tumor 5hmC - TEL AVIV, Israel and OSLO, Norway, Nov. 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two posters featuring GLIX1 were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting.
PRNewsWire • Nov 16, 2026

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors In an HR-proficient ovarian cancer patient-derived xenograft model, low-doses of GLIX1 plus olaparib demonstrated statistically significant tumor growth inhibition versus vehicle control, and tumor growth inhibition comparable to cisplatin TEL AVIV, Israel, and OSLO, Norway, Oct. 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced today that the companies presented data at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026) demonstrating synergy between GLIX1 and multiple PARP inhibitors (PARPi) in homologous recombination (HR)-proficient ovarian cancer cell lines and in an in vivo patient-derived xenograft (PDX) model.
PRNewsWire • Oct 23, 2026

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.
PRNewsWire • Oct 8, 2026

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd.
PRNewsWire • Sep 10, 2026

BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 31, 2026

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model - - Announced additional data demonstrating strong synergistic effect between GLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer xenograft model - - Management to host conference call today, August 31, at 8:30 am EDT - TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.
PRNewsWire • Aug 31, 2026

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per ADS (or per ADS equivalent) through a registered direct offering.
PRNewsWire • Aug 28, 2026

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.
PRNewsWire • Aug 25, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BioLineRx Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.